Navigation Links
BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
Date:11/8/2012

ersify its existing portfolio. 

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it is marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation with naloxone for the treatment of opioid dependence.  BEMA Buprenorphine for chronic pain is licensed on a worldwide basis to Endo Health Solutions.  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL™ is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
2. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
3. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
4. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
5. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
6. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
7. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
8. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
9. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
10. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
11. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Presented at American Academy of Dermatology Summer ... NeoStrata today announced,findings from an ongoing 12-week ... applied LCD (coal tar) solution (Psorent(TM)) versus,calcipotriol ... psoriasis.,Specifically, results of an interim analysis reveal ...
... 30 An overwhelming number of,Americans with memory ... their,doctors despite visits within the past six months, ... participants in the Alzheimer,s Foundation of,America (AFA) National ... the results at a poster session at the ...
Cached Medicine Technology:Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis 2Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis 3Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors 2Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors 3
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
(Date:7/9/2014)... have found that fecal transplantation is effective and safe ... This is the result of a study led by ... Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. The ... advance of print in the American Journal of ... C. diff , has increased to epidemic proportions over ...
(Date:7/9/2014)... July 9, 2014 There has been a ... UT Southwestern Medical Center using MyChart, the online, interactive ... results, communicate with their healthcare providers, schedule appointments, and ... of patients actively using MyChart each year ... year increased more than 10-fold, according to a study ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... , , , , ... , , , AUDIO: , ... approximately 30cm from the bullet... , , Click here for ... , , , , , ... , , , , , University of Southampton researchers, with assistance from the Ministry of ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... American Cancer Society,is looking for individuals with or without ... the battle against cancer to serve on peer,review committees ... the,organization,s research and training grants. These "stakeholders" have,often had ... had a,family member with cancer, having been a cancer ...
... will show that dental mercury uses contribute to high ... show, for the first time, that dental mercury air,emissions ... US EPA estimates, WASHINGTON, Nov.12 The U.S. ... Reform,Committee will hold a hearing on Wednesday, Nov. 14, ...
... 12 Leading health care risk,management and insurance ... for the period ended Sept. 30, 2007, including ... first nine months of the year. The ... insurance and integrated risk management products,and services for ...
... assistance services affect quality of,patient care, CHICAGO, ... is failing to provide language assistance services required,by ... with the Office for,Civil Rights of the U.S. ... was filed by the American Federation of State, ...
... French . , The Zaire species of Ebolavirus ... species. It alone is responsible for 88% of human ... 1976. It was moreover the species involved in the ... of Congo (DRC) .In spite of the mass of ...
... Nov. 12 Verus Pharmaceuticals, Inc., a,pediatric-oriented specialty pharmaceutical ... to President & Chief Executive Officer.,Prior to the promotion, ... a result of the promotion, Cam L. Garner now ... to announce this well-deserved promotion," said Cam L.,Garner. "As ...
Cached Medicine News:Health News:American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 2Health News:Environmental Impacts of Dental Mercury Focus of U.S. House Oversight Hearing Wednesday 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 3Health News:Language Assistance Lacking at Resurrection Hospitals 2Health News:Language Assistance Lacking at Resurrection Hospitals 3Health News:New genetic lineage of Ebola virus discovered in great apes 2Health News:New genetic lineage of Ebola virus discovered in great apes 3Health News:Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer 2Health News:Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer 3
... Cougar is an Anterior Spinal Implant ... elasticity approximating that of cortical bone. The ... structural requirements of anterior column support, while ... load sharing design. Incorporates an anatomic design ...
... anterior column support for single or multilevel ... L5. The system consists of one or ... are stacked to a desired height, accommodating ... Reinforced Polymer material emulates the biomechanical properties ...
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
Anterior Interbody fusion with proven clinical performance. Large hole design. Request info fda status for sale....
Medicine Products: